Selenium and sulindac are synergistic to inhibit intestinal tumorigenesis in Apc/p21 mice

Journal of Hematology and Oncology

Volumn 6, Issue 1, 2013, Pages

  Bi, Xiuli ^a,b   Pohl, Nicole ^b   Dong, Huali ^b   Yang, Wancai ^b,c  

^a LIAONING UNIVERSITY   (China)

^b UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^c XINXIANG MEDICAL UNIVERSITY   (China)

Author keywords

Cancer prevention; Methylation; Selenium; Sulindac; Wnt catenin

Indexed keywords

BETA CATENIN; PROTEIN P27; PROTEIN P53; SELENIUM; STRESS ACTIVATED PROTEIN KINASE 1; SULINDAC; APC PROTEIN; CDKN1A PROTEIN, MOUSE; CYCLIN DEPENDENT KINASE INHIBITOR 1A; CYCLIN DEPENDENT KINASE INHIBITOR 1B; NONSTEROID ANTIINFLAMMATORY AGENT;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER INCIDENCE; CANCER INHIBITION; CANCER PREVENTION; CONTROLLED STUDY; DIETARY SUPPLEMENT; DRUG EFFECT; DRUG POTENTIATION; ENZYME REPRESSION; INTESTINE TUMOR; MOUSE; NONHUMAN; PROMOTER REGION; PROTEIN EXPRESSION; PROTEIN INDUCTION; PROTEIN PHOSPHORYLATION; ANIMAL; CELL TRANSFORMATION; DISEASE MODEL; DNA METHYLATION; DRUG COMBINATION; FEMALE; GENETICS; MALE; METABOLISM; MOUSE MUTANT; PATHOLOGY; PHOSPHORYLATION; PHYSIOLOGY; REAL TIME POLYMERASE CHAIN REACTION; WESTERN BLOTTING;

ADENOMATOUS POLYPOSIS COLI PROTEIN; ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; BETA CATENIN; BLOTTING, WESTERN; CELL TRANSFORMATION, NEOPLASTIC; CYCLIN-DEPENDENT KINASE INHIBITOR P21; CYCLIN-DEPENDENT KINASE INHIBITOR P27; DISEASE MODELS, ANIMAL; DNA METHYLATION; DRUG SYNERGISM; DRUG THERAPY, COMBINATION; FEMALE; INTESTINAL NEOPLASMS; MALE; MICE; MICE, KNOCKOUT; MITOGEN-ACTIVATED PROTEIN KINASE 8; PHOSPHORYLATION; PROMOTER REGIONS, GENETIC; REAL-TIME POLYMERASE CHAIN REACTION; SELENIUM; SULINDAC; TUMOR SUPPRESSOR PROTEIN P53;

MLCS; MLOWN;

EID: 84872268519     PISSN: None     EISSN: 17568722     Source Type: Journal    
DOI: 10.1186/1756-8722-6-8     Document Type: Article

References (35)

1. Giardiello FM, Hamilton SR, Krush AJ, Piantadosi S, Hylind LM, Celano P, Booker SV, Robinson CR, Offerhaus GJ: Treatment of colonic and rectal adenomas with sulindac in familial adenomatous polyposis. N Engl J Med 1993, 328:1313-1316.
2. Nugent KP, Farmer KC, Spigelman AD, Williams CB, Phillips RK: Randomized controlled trial of the effect of sulindac on duodenal and rectal polyposis and cell proliferation in patients with familial adenomatous polyposis. Br J Surg 1993, 80:1618-1619.
3. Yang W, Velcich A, Mariadason J, Nicholas C, Corner G, Houston M, Edelmann W, Kucherlapati R, Holt PR, Augenlicht LH: P21(waf1/cip1) is an important determinant of intestinal cell response to sulindac in vitro and in vivo. Cancer Res 2001, 61:6297-6302.
4. Yang W, Bancroft L, Liang J, Zhuang M, Augenlicht LH: P27kip1 in intestinal tumorigenesis and chemoprevention in the mouse. Cancer Res 2005, 65:9363-9368.
5. Boolbol SK, Dannenberg AJ, Chadburn A, Martucci C, Guo XJ, Ramonetti JT, Abreu-Goris M, Newmark HL, Lipkin ML, DeCosse JJ, Bertagnolli MM: Cyclooxygenase-2 overexpression and tumor formation are blocked by sulindac in a murine model of familial adenomatous polyposis. Cancer Res 1996, 56:2556-2560.
6. Reddy BS, Kawamori T, Lubet RA, Steele VE, Kelloff GJ, Rao CV: Chemopreventive efficacy of sulindac sulfone against colon cancer depends on time of administration during carcinogenic process. Cancer Res 1999, 59:3387-3391.
7. Yang W, Mathew J, Velcich A, Edelmann W, Kucherlapati R, Lipkin M, Yang K, Augenlicht LH: Targeted inactivation of the p21(waf1/cip1) gene enhances apc-initiated tumor formation and the tumor-promoting activity of a western-style high-risk diet by altering cell maturation in the intestinal mucosal. Cancer Res 2001, 61:565-569.
8. Yang W, Bancroft L, Augenlicht LH: Methylation in the p21(waf1/cip1) promoter of apc(+/-), p21(+/-) mice and lack of response to sulindac. Oncogene 2005, 24:2104-2109.
9. Greenwald P, Milner JA, Anderson DE, McDonald SS: Micronutrients in cancer chemoprevention. Cancer Metastasis Rev 2002, 21:217-230.
10. Stratton MS, Reid ME, Schwartzberg G, Minter FE, Monroe BK, Alberts DS, Marshall JR, Ahmann FR: Selenium and inhibition of disease progression in men diagnosed with prostate carcinoma: Study design and baseline characteristics of the 'watchful waiting' study. Anticancer Drugs 2003, 14:595-600.
11. Stratton MS, Reid ME, Schwartzberg G, Minter FE, Monroe BK, Alberts DS, Marshall JR, Ahmann FR: Selenium and prevention of prostate cancer in high-risk men: The negative biopsy study. Anticancer Drugs 2003, 14:589-594.
12. Peters U, Takata Y: Selenium and the prevention of prostate and colorectal cancer. Mol Nutr Food Res 2008, 52:1261-1272.
13. Fang W, Han A, Bi X, Xiong B, Yang W: Tumor inhibition by sodium selenite is associated with activation of c-jun nh2-terminal kinase 1 and suppression of beta-catenin signaling. Int J Cancer 2010, 127:32-42.
14. Davis CD, Uthus EO: Dietary selenite and azadeoxycytidine treatments affect dimethylhydrazine-induced aberrant crypt formation in rat colon and DNA methylation in ht-29 cells. J Nutr 2002, 132:292-297.
15. Li Y, Tollefsbol TO: Impact on DNA methylation in cancer prevention and therapy by bioactive dietary components. Curr Med Chem 2010, 17:2141-2151.
16. Clark LC, Combs GF Jr, Turnbull BW, Slate EH, Chalker DK, Chow J, Davis LS, Glover RA, Graham GF, Gross EG, Krongrad A, Lesher JL Jr, Park HK, Sanders BB Jr, Smith CL, Taylor JR: Effects of selenium supplementation for cancer prevention in patients with carcinoma of the skin. A randomized controlled trial. Nutritional prevention of cancer study group. JAMA 1996, 276:1957-1963.
17. Bertagnolli MM, Eagle CJ, Zauber AG, Redston M, Solomon SD, Kim K, Tang J, Rosenstein RB, Wittes J, Corle D, Hess TM, Woloj GM, Boisserie F, Anderson WF, Viner JL, Bagheri D, Burn J, Chung DC, Dewar T, Foley TR, Hoffman N, Macrae F, Pruitt RE, Saltzman JR, Salzberg B, Sylwestrowicz T, Gordon GB, Hawk ET: Celecoxib for the prevention of sporadic colorectal adenomas. N Engl J Med 2006, 355:873-884.
18. Flossmann E, Rothwell PM: Effect of aspirin on long-term risk of colorectal cancer: Consistent evidence from randomised and observational studies. Lancet 2007, 369:1603-1613.
19. Meyskens FL Jr, McLaren CE, Pelot D, Fujikawa-Brooks S, Carpenter PM, Hawk E, Kelloff G, Lawson MJ, Kidao J, McCracken J, Albers CG, Ahnen DJ, Turgeon DK, Goldschmid S, Lance P, Hagedorn CH, Gillen DL, Gerner EW: Difluoromethylornithine plus sulindac for the prevention of sporadic colorectal adenomas: A randomized placebo-controlled, double-blind trial. Cancer Prev Res (Phila) 2008, 1:32-38.
20. Lippman SM, Klein EA, Goodman PJ, Lucia MS, Thompson IM, Ford LG, Parnes HL, Minasian LM, Gaziano JM, Hartline JA, Parsons JK, Bearden JD 3rd, Crawford ED, Goodman GE, Claudio J, Winquist E, Cook ED, Karp DD, Walther P, Lieber MM, Kristal AR, Darke AK, Arnold KB, Ganz PA, Santella RM, Albanes D, Taylor PR, Probstfield JL, Jagpal TJ, Crowley JJ, et al: Effect of selenium and vitamin e on risk of prostate cancer and other cancers: The selenium and vitamin e cancer prevention trial (select). Jama 2009, 301:39-51.
21. Yao J, Eu KW, Seow-Choen F, Cheah PY: Down-regulation of p27 is a significant predictor of poor overall survival and may facilitate metastasis in colorectal carcinomas. Int J Cancer 2000, 89:213-216.
22. Zhang H, Sun XF: Loss of p27 expression predicts poor prognosis in patients with dukes' b stage or proximal colorectal cancer. Int J Oncol 2001, 19:49-52.
23. Theard D, Raspe MA, Kalicharan D, Hoekstra D, van ISC: Formation of ecadherin/beta-catenin-based adherens junctions in hepatocytes requires serine-10 in p27(kip1). Mol Biol Cell 2008, 19:1605-1613.
24. Matsuzawa SI, Reed JC: Siah-1, sip, and ebi collaborate in a novel pathway for beta-catenin degradation linked to p53 responses. Mol Cell 2001, 7:915-926.
25. Sadot E, Geiger B, Oren M, Ben-Zeev A: Down-regulation of beta-catenin by activated p53. Mol Cell Biol 2001, 21:6768-6781.
26. Tong C, Yin Z, Song Z, Dockendorff A, Huang C, Mariadason J, Flavell RA, Davis RJ, Augenlicht LH, Yang W: C-jun nh2-terminal kinase 1 plays a critical role in intestinal homeostasis and tumor suppression. Am J Pathol 2007, 171:297-303.
27. Hu D, Bi X, Fang W, Han A, Yang W: Gsk3beta is involved in jnk2-mediated beta-catenin inhibition. PLoS One 2009, 4:e6640.
28. Hu D, Fang W, Han A, Gallagher L, Davis RJ, Xiong B, Yang W: C-jun nterminal kinase 1 interacts with and negatively regulates wnt/betacatenin signaling through gsk3beta pathway. Carcinogenesis 2008, 29:2317-2324.
29. Song Z, Tong C, Liang J, Dockendorff A, Huang C, Augenlicht LH, Yang W: Jnk1 is required for sulindac-mediated inhibition of cell proliferation and induction of apoptosis in vitro and in vivo. Eur J Pharmacol 2007, 560:95-100.
30. Velcich A, Yang W, Heyer J, Fragale A, Nicholas C, Viani S, Kucherlapati R, Lipkin M, Yang K, Augenlicht L: Colorectal cancer in mice genetically deficient in the mucin muc2. Science 2002, 295:1726-1729.
31. Fodde R, Edelmann W, Yang K, van Leeuwen C, Carlson C, Renault B, Breukel C, Alt E, Lipkin M, Khan PM, Kucherlapati R: A targeted chaintermination mutation in the mouse apc gene results in multiple intestinal tumors. Proc Natl Acad Sci U S A 1994, 91:8969-8973.
32. Xu D, Wang Q, Jiang Y, Zhang Y, Vega-Saenzdemiera E, Osman I, Dai W: Roles of polo-like kinase 3 in suppressing tumor angiogenesis. Exp Hematol Oncol 2012, 1:5.
33. Lamba G, Gupta R, Lee R, Ambrale S, Liu D: Current management and prognostic features for gastrointestinal stromal tumor (gist). Exp Hematol Oncol 2012, 1:14.
34. Bi X, Pohl NM, Yin Z, Yang W: Loss of jnk2 increases intestinal tumor susceptibility in apc1638+/- mice with dietary modulation. Carcinogenesis 2011, 32:584-588.
35. Bi X, Fang W, Wang LS, Stoner GD, Yang W: Black raspberries inhibit intestinal tumorigenesis in apc1638+/- and muc2-/- mouse models of colorectal cancer. Cancer Prev Res (Phila) 2010, 3:1443-1450.